Kazatomprom Reports 17 Production Increase in Third Quarter Nvidia Stock Approaches Critical Technical Level Amid Market Scrutiny Secretary of State Rubio Discusses US Energy Sales With Indias Modi Amid Iran Conflict Disruptions Indias REITs Diversify Beyond Office Spaces A Potential Wealth Creation Avenue for Retail Investors Google Redesigns Homepage Search Box to Integrate AI Features Security Incident Near White House Raises Geopolitical Concerns MAT Q1 2026 Earnings NarrowerthanExpected Loss Drives Modest Stock Uptick SYNA Q1 2026 Earnings EPS Beats Estimates by 6 Stock Surges ETSY Q1 2026 Earnings Earnings Beat Expectations with Strong EPS Surprise TIC Solutions Inc Q1 2026 Earnings Deep EPS Miss Highlights Ongoing Cost Pressures RBLX Q1 2026 Earnings NarrowerThanExpected Loss Boosts Investor Sentiment TE Connectivity Q1 2026 Earnings Modest EPS Beat Amid Steady Operational Execution Scholar Rock Holding SRRK Pulls Back 191 as Resistance at 5215 Caps Gains Waters Corporation WAT Edges Higher as Shares Consolidate Near Resistance Eikon Therapeutics Inc EIKN Slips 224 as Stock Holds Above Key Support Level Backblaze Inc BLZE Edges Higher in Quiet Trading Holding Above Key Support Levels Playtika Holding Corp PLTK Faces Headwinds as Shares Decline Near Key Support Kathleen Kennedy Townsend Sells Cape Cod Home for 16 Million Quick Offer Highlights Luxury Demand BNL Q1 2026 Earnings Strong EPS Surprise of 53 Exceeds Analyst Expectations Hudson Pacific Properties HPP Rebounds Toward Resistance After Modest Gain Gossamer Bio Inc GOSS Q1 2026 Earnings WiderthanExpected Loss Weighs on Shares JPMorgan Banker Lorna Hajdini Countersues Accuser Over Sexual Assault Allegations CARE Q1 2026 Earnings Significant EPS Miss Despite Positive Stock Reaction i80 Gold Corp IAUX Q1 2026 Earnings NarrowerThanExpected Loss Signals Progress for Gold Developer Amplitude Q1 2026 Earnings EPS Misses Estimates as Stock Edges Higher WLKP Q1 2026 Earnings EPS Misses Estimates Amid Stable Distribution Units Edge Higher BLTE Q4 2025 Earnings WiderthanExpected Loss as PreRevenue Biotech Remains Focused on Clinical Development